Dimensional Fund Advisors LP Has $289.07 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals by 14.4%, acquiring an additional 293,360 shares and owning 3.78% of the company, valued at approximately $289 million.
• CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals, reducing his ownership to 436,973 shares, valued at $47 million, amidst a broader context of insider trading.
• Despite reporting a revenue of $1.05 billion, Jazz Pharmaceuticals had a loss of $8.25 per share for the quarter, missing estimates and reflecting on an overall negative net margin of 9.91%.

Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 14.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,328,430 shares of the specialty pharmaceutical company's stock after buying an additional 293,360 shares during the period. Dimensional Fund Advisors LP owned 3.78% of Jazz Pharmaceuticals worth $289,066,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Capital World Investors lifted its holdings in shares of Jazz Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after acquiring an additional 104,195 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after purchasing an additional 315,608 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock valued at $206,343,000 after purchasing an additional 74,501 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Jazz Pharmaceuticals by 8.3% during the 4th quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company's stock worth $120,071,000 after buying an additional 75,000 shares during the last quarter. Finally, Perpetual Ltd boosted its stake in Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after buying an additional 357,784 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on JAZZ. Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price for the company. Piper Sandler reissued an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Thirteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $181.43.

Jazz Pharmaceuticals Trading Up 1.3%

NASDAQ:JAZZ traded up $1.5060 during trading hours on Thursday, hitting $120.5760. 505,320 shares of the company were exchanged, compared to its average volume of 956,588. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of -17.89, a price-to-earnings-growth ratio of 7.51 and a beta of 0.34. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a fifty day simple moving average of $112.24 and a 200 day simple moving average of $117.15. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter last year, the firm posted $5.30 EPS. The company's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.